[The implications of thromboembolism in chronic heart failure].
The goal of investigation was to determine whether long-term anticoagulant therapy influences the mortality rate in CHF. The method consisted in the calculation of the annual death rate of the patients with CHF class III-IV NYHA: group A (controls)--who did not receive anticoagulant or antiplatelet therapy; group B--treated with Acenocumarol or Aspirin. The results show in group A, which included 150 patients, during the 5-year interval under study 30 deaths, representing an annual death rate of 4%. In group B, which included 325 patients of which 75 treated with Acenocumarol and 250 patients with aspirin, 20 deaths were recorded during the same 5-year interval, representing an annual death rate of 1.2%. Thus, the mortality risk proved to be 70% lower in group B than in the control group. It came out that the main mechanism of death in CHF is thrombembolism and in this circumstance anticoagulant or antiplatelet therapy would be essential.
Ambăruş
V
V
Clinica a III-a Medicală Cardiologie I. Enescu, Facultatea de Medicină, Universitatea de Medicină şi Farmacie Gr.T. Popa, Iaşi.
Rezuş
C
C
Ghiuru
Rodica
R
Ionescu
Simona
S
Manea
Paloma
P
Leuciuc
Elena
E
Artenie
R
R
Sandru
V
V
Cosovanu
A
A
D000074:Acenocoumarol / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D003196:Computer Graphics; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D012383:Romania / Q000453:epidemiology; D015996:Survival Rate; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology / Q000401:mortality*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D000074:Acenocoumarol; D001241:Aspirin